CVS is now selling a rival, generic version of Mylan's life-saving allergy treatment EpiPen at about a sixth of EpiPen's price, months after Mylan was eviscerated before Congress because of EpiPen's soaring cost. That's significantly lower than the sticker price for EpiPen, which is now well above $600 for two injectors.
The emergency allergy treatments are stocked in schools and carried by parents of children, and are used to stop anaphylaxis, a potentially fatal allergic reaction.
The syringes are filled with the hormone epinephrine, and they expire after a year. This is the lowest cash price for the drug in the market.
Mylan drew major flak past year after news broke that it had steadily increased the list price for an EpiPen two-pack from about $100 to more than $600 in less than a decade.
Sensex climbs up 173 points
Among other Asian markets, Shanghai Composite Index rose 0.26 per cent, while Hong Kong's Hang Seng was up 0.02 per cent. The market sentiment got a boost after IndusInd Bank and South Indian Bank cheered with better-than expected Q3 numbers.
The National Community Pharmacists Association recently called for a Congressional hearing on how pharmacy benefit managers have contributed to the "absurdly high" price.
President-elect Donald Trump jumped in the fray over skyrocketing drug prices Wednesday.
Mylan's generic version of the epinephrine auto-injector pen was launched in December and has the same drug formulation and device functionality as the original - a product that has been on the market for almost 30 years - and is administered in the same way.
Shares of most drugmakers sank nearly immediately after his comments and were still under pressure Thursday, though the decline in Mylan's stock outpaced most. At his first news conference as president-elect, Trump vowed to change the way the USA bids on drugs.